Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats (Q44333888)

2 December 2017

Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats (English)

1 reference

2 December 2017

0 references

0 references

Parkes H

1

1 reference

PubMed ID

11091024

2 December 2017

Sinclair JD

series ordinal

2

1 reference

2 December 2017

1 July 2000

1 reference

2 December 2017

1 reference

2 December 2017

21

1 reference

2 December 2017

3

1 reference

2 December 2017

215-221

1 reference

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Attenuation of alcohol drinking in tetrahydroisoquinoline-treated rats by morphine and naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signalling in a genetic model of high alcohol drinking.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Chronic naloxone results in prolonged increases in opiate binding sites in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Opiate agonists and antagonists discriminated by receptor binding in brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Review important concepts of receptor theory

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Drugs to decrease alcohol drinking

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

New treatment options for substance abuse from a public health viewpoint.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

The limited access paradigm: description of one method

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Chronic opioid antagonist treatment: assessment of receptor upregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

Naltrexone-induced opiate receptor supersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0741-8329%2800%2900091-4

7 January 2021

10.1016/S0741-8329(00)00091-4

Identifiers

DOI

1 reference

2 December 2017

1 reference

PubMed ID

11091024